BACKGROUND: In the past decade, migraine research has identified novel drug 
targets. In this review, we discuss recent data on emerging anti-migraine 
therapies.
MAIN BODY: The development of ditans, gepants and anti-calcitonin gene-related 
peptide monoclonal antibodies for the treatment of migraine is one of the 
greatest advances in the migraine field. Lasmiditan, rimegepant and ubrogepant 
will extend our therapeutic armamentarium for managing acute migraine attacks 
when triptans are not effective or contraindicated due to cardiovascular 
disorders. The monoclonal antibodies are migraine specific prophylactic drugs 
with high responder rates and favorable adverse event profiles. Furthermore, 
they offer convenient treatment regimens of 4- or 12-week intervals.
CONCLUSION: Collectively, novel migraine therapies represent a major progress in 
migraine treatment and will undoubtedly transform headache medicine.